NASDAQ: RZLT - Rezolute, Inc.

Lønnsomhet i seks måneder: -30.1%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Rezolute, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc.

flere detaljer
and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2014-05-01
ISIN US76200L3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rezolutebio.com
Цена ао 3.74
Prisendring per dag: -3.74% (3.74)
Prisendring per uke: -6.49% (3.85)
Prisendring per måned: -25.93% (4.86)
Prisendring over 3 måneder: -21.57% (4.59)
Prisendring over seks måneder: -30.1% (5.15)
Prisendring per år: +102.25% (1.78)
Prisendring over 3 år: +32.84% (2.71)
Prisendring over 5 år: +2 516.28% (0.1376)
Prisendring siden begynnelsen av året: -18.92% (4.44)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 1.65 8
P/E 0 0
EV/EBITDA -1.91 0
Total: 3.5

Effektivitet

Navn Betydning Karakter
ROA, % -53.39 0
ROE, % -57.73 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0326 10
Total: 9.4

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 237.06 10
Lønnsomhet EPS, % -61.99 0
Total: 6
Flere detaljer

Institusjoner Volum Dele, %
Federated Hermes, Inc. 10154327 0
Vivo Capital, LLC 3242842 38.52
Nantahala Capital Management, LLC 3075414 36.53
Stonepine Capital Management, LLC 2768656 32.89
First Manhattan Company 2680978 31.85
Blackstone Inc 1537684 18.27
Vanguard Group Inc 1407652 16.72
Caxton Corporation 1318967 15.67
Sphera Funds Management Ltd. 996710 11.84
Adage Capital Partners GP L.L.C. 631690 7.5

ETFDele, %Lønnsomhet for året, %Utbytte, %
iShares Micro-Cap ETF 0.05811 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.01284 27.77 1.68271
Dimensional U.S. Targeted Value ETF 0.00052 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.0002 30.76 1.47098
0.0225.411.66



Veileder Stillingstittel Betaling Fødselsår
Mr. Nevan Charles Elam J.D. Founder, CEO & Acting Chairman of the Board 973.65k 1967 (58 år)
Dr. Brian Kenneth Roberts M.D. Chief Medical Officer 738.86k 1975 (50 år)
Dr. Davelyn Eaves Hood M.B.A., M.D. Director and Head of Scientific & Patient Affairs N/A
Mr. Michael R. Deperro Senior VP & Head of Corporate Development N/A
Mr. Michael Covarrubias Senior VP & Head of Program & Portfolio Management N/A
Mr. Chris Milks VP & Head of Finance N/A
Dr. Raj Agrawal M.D. VP & Head of Ophthalmological Clinical Development N/A
Ms. Robyn Sweinhart VP & Head of Quality N/A
Mr. Daron G. Evans M.B.A., M.S. Chief Financial Officer N/A 1974 (51 år)
Ms. Erin O'Boyle Senior VP & Head of Clinical Operations

Adresse: United States, Redwood City. CA, 201 Redwood Shores Parkway - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.rezolutebio.com